Stay updated on Ruxolitinib vs BAT in Chronic GvHD Clinical Trial

Sign up to get notified when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The footer revision changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-29T11:13:05.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    A site-wide NIH notice was added, announcing a website transition and stating that some NIH content will use “Super Intelligence” in place of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-22T09:59:40.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The error page footer now displays revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-15T12:33:35.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The site footer revision identifier changed from v3.7.0 to v3.7.1. The study page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-08T13:12:38.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    403 Forbidden error is shown when accessing the study record, replacing the previous study content. This prevents users from viewing the trial details, documents, or locations.
    Difference
    19%
    Check dated 2026-09-24T18:27:49.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The page now shows a new Revision: v3.7.0 tag, replacing the previous Revision: v3.6.6, indicating the content was updated to a newer version.
    Difference
    0.0%
    Check dated 2026-09-17T20:02:07.000Z thumbnail image

Stay in the know with updates to Ruxolitinib vs BAT in Chronic GvHD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.